Uses of Cathy-K

Cathy-K is indicated in the treatment of breast cancer in postmenopausal women. Cathy-K belongs to the group of anti-cancer drugs, so it is very important to follow the way prescribed by the doctor to limit side effects and maximize the effectiveness of treatment.

Cathy-K belongs to the group of anti-cancer drugs and affects the immune system, made in the form of film-coated tablets, packing specifications: Box of 2 blisters x 14 tablets. The drug contains the main active ingredient, Anastrozole (1mg), indicated in the treatment of breast cancer in postmenopausal women.
1.1. Pharmacodynamics Anastrozole is an aromatase inhibitor, a non-steroidal anti-inflammatory drug, with high selectivity and potent action. In postmenopausal women, oestradiol is produced from the conversion of androstenedione to oestrone by the aromatase enzyme complex in peripheral tissues, which oestrone is then converted to oestradiol. Reducing the amount of oestradiol in the blood has an effect on breast cancer patients.
1.2. Pharmacokinetics After 2 hours of oral administration of Anastrozole, the drug is rapidly absorbed and reaches maximum plasma concentrations. Anastrozole is slowly eliminated with a half-life of 40-50 hours. Food may decrease the rate of absorption of Anastrozole, but it is unlikely to have a clinically significant effect if taken as a single daily dose. There is no evidence that the pharmacokinetic parameters of Anastrozole are dose or duration dependent or the age of the postmenopausal woman.
In postmenopausal female patients, the active substance Anastrozole is extensively metabolised by N-dealkylation, glucuronidation and hydroxidation. Metabolism products are excreted mainly as seawater, with no aromatase inhibitory effect.

Reference dose of Cathy-K is as follows:
Dosage for adults: 01 Cathy-K tablet per day; Dosage for patients with hepatic impairment: No dose adjustment of Cathy-K is required in patients with mild hepatic impairment; Dosage for renal impairment: No dose adjustment of Cathy-K in patients with mild to moderate renal impairment. The above Cathy-K dosage is for reference only. The specific dose of Cathy-K will depend on your condition and disease progression. To get the right dose of Cathy-K, patients need to consult with their doctor or pharmacist.

Do not use Cathy-K for the following subjects:
Pre-menopausal women; Pregnant and lactating women; Patients with severe renal failure, with creatinine clearance less than 20ml/min; People with moderate and severe liver disease; Hypersensitivity to the active ingredient Anastrozole or any of the excipients of Cathy-K; Oestrogen-containing drugs, Tamoxifen should not be used concurrently with Cathy-K; Cathy-K is contraindicated in children.

Common side effects:
Mild or moderate hot flashes; Attenuate; Joint pain/stiffness; Vaginal dryness; Hair loss ; Rash, skin rash; Nausea, diarrhea; Headaches; Increased levels of alkaline phosphatase, alanine aminotranferase and aspartate aminotransferase; Vaginal bleeding; Anorexia. Rare side effects:
Erythema multiforme; Steven-Johnson syndrome ; Allergic reactions such as angioedema, urticaria and anaphylaxis. In order to prevent dangerous side effects, during treatment, if there are any unusual symptoms suspected of using Cathy-K, the patient should notify the treating doctor for treatment. timely mind.

Before treatment with Cathy-K, it is necessary to confirm the menopausal status by biochemical testing in patients with suspected endocrine status. Women at risk or with osteoporosis should have their bone density assessed with a Dexa scanner prior to treatment with Cathy-K and periodically thereafter. Above is information about uses, dosage and precautions when using Cathy-K. To avoid interactions, before being prescribed Cathy-K, the patient should inform the doctor about the drugs they are using, including vitamins, herbs, and functional foods.